Background: Coronary stent implantation is currently one of the most performed cardiovascular interventions, but requires a long-term therapy with anti-platelet agents to prevent stent thrombosis. Stents with microstructured surfaces should improve stent vascularisation, reduce thrombotic events and consequentially shorten the length of anti-thrombotic therapy.
graphically etched on silicon plates, subsequently coated with silicon carbide. As controls, smooth silicon plates, bare metal substrates, and cell culture plastic were used. The migration of human umbilical vein endothelial cell (HUVECs) was assessed in a modified barrier assay using cell culture inserts (n¼10). 8h/24h after cell seeding, inserts were removed and cell migration was monitored for 2, 20, 30, 40, 60, and 72 hours. Actin cytoskeleton was visualised with green phalloidin. Platelet concentrate or whole blood were incubated on the different surfaces in static and flow conditions to investigate surface thrombogenicity (n¼10). For cell counting, P-selectin antibody conjugated with fluorescein was used. Images were taken with an incident light fluorescent microscope used for studies of non-transparent objects. Results: Comparing different types of structured surfaces, improved endothelial cell migration over 72h was observed for 4-5 mm pillow-like structures, whereas smaller spiky structures (2 mm), hollows, and smooth surfaces (i.e. smooth silicon plates, bare metal substrates) had a negative effect on endothelial migration. Moreover, substrate specific interactions between the tested endothelial cells and the structure relief could be detected. The thrombogenicity assays under static and flow conditions performed using whole blood and platelet concentrate showed that the platelet adhesion was reduced on larger structures as compared to smaller sharp-edged structures, hollows, or the smooth surfaces. Conclusions: Microstructured surfaces have strong influence on endothelial cell migration and platelet adhesion. These results open new possibilities to design stent surfaces which improve adherence and migration of endothelial cells, and inhibit thrombogenic processes.
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The Impact Of Triple Anti-Platelet Therapy For Background: This study was conducted to evaluate the endothelialization and the inflammatory responses depending on the administration duration of triple anti-platelet therapy at overlapping bioabsorbable polymer coated biolimus-eluting stents (BESs) in a porcine coronary model. Methods: We successfully deployed 36 overlapping BESs for the left anterior descending coronary and left circumflex artery or right coronary artery in 18 noninjured pigs. Total pigs were divided into 3 groups (12 overlapping stents of 6 pigs in each group) as follows: group I received aspirin 100mg and clopidogrel 75mg daily for 8 weeks, group II received aspirin 100mg and clopidogrel 75mg daily for 8 weeks and cilostazol 200mg daily for initial 4 weeks, group III received aspirin 100mg, clopidogrel 75mg, and cilostazol 200mg daily for 8 weeks. Follow-up coronary angiograms and histomorphometric and histopahtologic analyses at overlapping and non-overlapping segments were performed respectively. Results: Inflammation score was similar between overlapping and non-overlapping segments in all pigs (1.2AE0.33 vs. 1.1AE0.17, p¼0.117). The neointima area (NA) and percent area stenosis (%AS) at overlapping segments were not significantly different among 3 groups. However, at non-overlapping segments, NA and %AS in group III were significantly smaller than those in group I (2.3AE0.50 mm2 vs. 1.8AE0.43 mm2, p¼0.037; 48.9AE12.85 % vs. 37.7AE9.08 %, p¼0.031). Conclusions: Our study shows that BES appears to be reliable on the inflammatory response at overlapping segments as well as non-overlapping segments. Long-term administration of cilostazol is more effective in reducing neointimal formation at nonoverlapping segments of BESs in a porcine coronary model. Background: Renal sympathetic denervation (RDN) has been shown to sustainably reduce BP. We report preclinical results using perivascular (adventitial) injection of small volumes of dehydrated alcohol (EtOH) via a novel drug delivery catheter. Methods: The three-needle delivery device, (Peregrine SystemÔ, Ablative Solutions, Inc.) was introduced via the femoral artery into renal arteries of swine using fluoroscopic guidance. Following deployment of the needles into the perivascular space, EtOH was injected circumferentially. Three doses of EtOH/renal artery (0.15, 0.30, and 0.60 ml) and sham (0.4 ml saline) control were evaluated at 2-weeks. The 0.3 ml dose was studied at 3-mos. (n¼6). Renal tissue norepinephrine (NE) was used as a surrogate marker of the effectiveness of RDN. Renal NE was also measured in 20 (naive control) kidneys. Results: Histopathology at 2-wks, and 3-mos. revealed substantial circumferential sympathetic nerve injury, at 2-10 mm depth from the intima. At 3-mos, the nerves exhibited a range of injury from focal regions of nerve swelling with minimal cellular infiltrates to almost complete neurolysis (typically replaced with fibrous tissue). The injury and the NE levels reduction were dose-dependent, with highly significant NE reductions at all doses compared to the sham and naïve groups. At 2 weeks, the mean renal NE reductions were 52%, 77% and 87%, respectively for the 3 doses (p < 0.01). At 3 mos. the 0.3 ml dose showed a mean renal NE reduction of 69% compared to the controls (p < 0.01). Angiographically, there was no evidence of vascular injury, stenosis or negative remodeling at any time point. Histopathology confirmed that the integrity of the renal artery was maintained, and at 3 months the treated area appeared healthy and with advanced healing. There were no systemic or renal toxic effects noted in any animal. Safety was further confirmed in a separate study in which 0.6 ml of EtOH was injected directly into each r Conclusions: Circumferential and deep peri-adventitial delivery of low doses of EtOH appears to be a simple, safe, predictable and viable alternative to energy-based systems to achieve substantial, sustained renal sympathetic denervation.
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Thrombogenicity Of Novel Polyphosphazene Surface-modified Coronary Stent Compared To Standard Bare Metal Stent In Swine Shunt Model
Kenichi Sakakura 1 , Qi Cheng 1 , Fumiyuki Otsuka 1 , Kazuyuki Yahagi 1 , Mark Barakat 2 , Jane Ren 2 , Elena Ladich 1 , Frank D. Kolodgie 1 , Renu Virmani 1 1 CVPath Institute, Inc., Gaithersburg, MD, 2 CeloNova BioSciences, Inc., San Antonio, TX Background: Late stent thrombosis and long-term dual antiplatelet therapy (DAPT) are limitations of current drug-eluting stents (DES), and restenosis remains the limitation of bare-metal stents (BMS). The COBRA PzF stent (CeloNova BioSciences, San Antonio, TX) with PolyzeneÒ-F (PzF) surface modification was designed to resist thrombosis and inflammation. We assessed the thrombogenicity of the COBRA PzF stent compared to COBRA BMS and Multi-Link Vision in the swine shunt model. Methods: A total of 12 stents (6 COBRA PzF stents, 3 COBRA BMS, and 3 Vision BMS) were deployed to custom-made elastic silicone tubes (SYLGARDÒ-184), in swine. An ex vivo arterio-venous shunt model was established with the tubing containing stents and maintained at 37 C. Following continuous 1 hr blood flow, the stents were fixed with 10% formalin. Each stent was bisected longitudinally and one half of the stent was submitted for immunohistochemistry using an antibody against platelet (CD61 and CD42b), and evaluated by confocal microscopy while the other half of the stent was process for scanning electron microscopy (SEM). Results: Mean fluorescent intensity of platelets was significantly less in the COBRA PzF (74.5AE1.3 AU) compared to COBRA BMS (97.8AE6.7 AU, P<0.05) or Vision BMS (108.2AE6.9 AU, P<0.01). Percent thrombus area by SEM was significantly less in the COBRA PzF (5.6%) compared to COBRA BMS (7.0%, P<0.05) or Vision BMS (69.1%, P<0.001). Conclusions: The COBRA PzF stent significantly reduces thrombogenicity in the swine shunt model compared to Cobra BMS and Vision BMS. TUESDAY, OCTOBER 29, 2013, 3:30 PM-5:30 PM 
